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Abstract The outlook for metastatic melanoma to the brain
is dismal. New therapeutic avenues are therefore needed.
The anti-metastatic mechanisms that may underpin the
effects of low molecular weight heparins (LMWHs) in in
vitro and preclinical melanoma models warrant translating
to a clinical setting. This review outlines a rationale that
supports our proposal that metastatic melanoma to the brain
is a clinical setting in which to study the anti-metastatic
potential of LMWHs. Prevention or delay of brain
metastases in melanoma is a clinically relevant and
measurable target. Studies to explore the effect of anti-
coagulants on cancer survival are underway in other
malignancies such as lung, pancreas, ovary, breast, and
stomach cancer. However, no study to our knowledge has a
methodology that could produce clinical evidence in
support of a mechanism for whatever benefit may be seen.
The setting we propose would allow translation of the
molecular knowledge of the metastatic pathways mediated
by platelets and the selectins—all potential targets of
heparin—in a “time to appearance” of brain metastases
endpoint. Since brain metastases are so common and they
have a singularly adverse impact on survival, the “biolog-
ical neuroprotection” model we propose in metastatic
melanoma could provide the translational evidence to
support the benefit of LMWHs in melanoma. More
significantly, this would open the door to a wider “anti-
metastatic” approach that could have much greater impact
in patients with minimal disease being treated in adjuvant
settings for the more common malignancies such as breast
and colon cancer.
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1 Introduction
The benefits from using anticoagulants in the treatment of
patients with cancer may arise from two clinically different
but biologically intertwined routes: direct effects (treatment
or prevention) on thrombotic complications of malignancy
and postulated anti-metastatic cancer effects.
From early laboratory and preclinical studies, melanoma
may be a malignancy that would benefit from anticoagulant
agents. Unlike pancreatic cancer [1], melanoma is not
highly thrombogenic, and the clinical benefit suggested is
unlikely to be solely due to the prevention of venous
thromboembolism [2]. Preclinical experiments in the 1980s
of anticoagulants in cancer treatment led to some poorly
designed underpowered clinical trials which suggested
improved survival in small cell lung cancer (SCLC) and
melanoma. These two malignancies have three things in
common: a relatively low incidence of thrombosis [2, 3],
neuroectodermal origin, and early metastasis, often to the
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in terms of sensitivity to conventional treatments. The
exquisite radiosensitivity of SCLC has led to survival gains
through the neuroprotective strategy of prophylactic cranial
irradiation [4] whereas melanoma is relatively radioresistant.
However, if a method of neuroprotection can be found for
melanoma, similar survival benefits to those in SCLC may
result.
These almost unique clinical properties of malignant
melanoma—a tendency for indiscriminate and multiple
metastases and lethal consequences of brain metastases,
coupled to the lack of confounding parameters of thrombo-
philia or a neuroprotective strategy—suggest melanoma as
a model malignancy to study the anti-metastatic potential of
low molecular weight heparins (LMWHs). This paper
outlines the rationale supporting this proposal.
2 Brain metastases in melanoma
The high mortality in melanoma patients relates to the high
incidence of brain metastases; the median survival of
unselected melanoma patients with brain metastases is only
2–4 months [5]. Melanoma cells appear to have substantial
neurotropism; it is the fourth most common primary site to
metastasize to the brain [6]. Melanoma accounts for 10% of
all brain metastases and has the second highest incident
proportion percentage [7]; up to 13% of patients with
regional disease (AJCC stage III) [8], 18–46% of stage IV
patients [6, 8], with a prevalence of up to 75% at autopsy
[8–11].
It was hoped that two cytotoxic agents that cross the
blood–brain barrier (BBB) (temozolomide and/or fotemus-
tine) would improve survival. Unfortunately, neither drug
provided any statistical advantage compared with the
current gold standard, dacarbazine (DTIC) [12, 13]. This
probably reflects the poor overall chemosensitivity of
melanoma, although fotemustine [12] did fare somewhat
better than dacarbazine in demonstrating a delay in the
onset of brain metastases; the median time to brain
metastases was 22.7 months (95% confidence interval
(CI), 9.62–23.33) in the fotemustine arm versus 7.2 months
(95% CI, 6.28–11.70) in the DTIC arm (P=.059). This just
failed to translate into an overall survival advantage;
7.3 months (95% CI, 6.01–8.84) in the fotemustine arm
versus 5.6 months (95% CI, 5.03–6.54) in the DTIC arm
(P=.067 in the intent-to-treat population) which may
reflect an underpowered study. Nevertheless, it strongly
suggests that a survival benefit could accompany better
CNS control of melanoma metastases and that a strategy
of “biological interference” with the metastatic process to
the brain may result in survival benefit for patients with
advanced melanoma.
3 Elements of neuroprotective strategies
The data from the above mentioned phase III trial [12]s h o w
that 20% of patients had brain metastases at study entry and
20% developed them over the assessment period of around
6 months. It is unlikely that all the brain metastases that
develop post-randomization result from pre-implanted mel-
anoma cells. It is more likely that a proportion of these have
resulted from an ongoing process of melanoma cells shed
from other metastases continuously arriving in the microcir-
culation of the brain—slowing down, attaching to endothe-
lium, and finally, successfully implanting.
A neuroprotection model of “biological interference”
would assume that BBB invasion by melanoma cells is a
stochastic event, i.e., occurs randomly on a background of a
predictable continuous process, thus requiring continuous
prophylaxis. This model can be broken down into three
components:
(1) Cytoreduction—i.e., reducing the burden of BBB
implanted cells.
(2) Inactivation of the “metastatic niche”—i.e., interfering
with the mechanisms driving invasion.
(3) Prevent implantation—i.e., interfering with the process
of endothelial cellular attachment.
This model differs to that of SCLC mostly because the
conventional modalities of chemotherapy and radiotherapy
achieve all the above stated components through the
exquisite sensitivity of SCLC to these treatments. Thus,
cytoreduction and inactivation are achieved by the chemo-
therapy and the radiotherapy while further implantation is
reduced by the systemic response to chemotherapy; the
efficacy of this strategy is mostly seen in patients who have
achieved complete or consolidated partial response with
radiotherapy [4].
In melanoma, this is not possible as we have no agents
that can deliver this “neuroprotective” component through
significant cancer cell kill. However, if a strategy of
continual “inactivation” and “interference” with the meta-
static process can be developed to complement a cytotoxic
induction phase, however modest, one may produce a
survival benefit.
4 Coagulation pathways and the metastatic process
Cancer cells are continuously shed into the circulation
either from the primary or from established metastases.
However, the metastatic process is inefficient and cell
survival in the circulation is low due to a combination of
shear forces, phagocytosis, and obstruction within capillary
beds. Only 1.5% of nonhematogenous cells injected into
the bloodstream survive for more than 24 h [14].
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process can, simplistically, be categorized as coagulation-
dependent and coagulation-independent. These insights
have existed for more than 30 years [15]. Although there
is some evidence that some of the coagulation factors may
also be involved in coagulation-independent promotion of
metastasis (such as tissue factor [16]), it appears that the
successful negotiation of the intravascular phase of the
cancer cell journey is heavily dependent on mechanical and
signaling interactions that would promote thrombosis in the
physiological state. There is unequivocal evidence of the
interactions between disseminating tumor cells and blood
cells, mainly platelets [17–19]. Initial support for an active
role of platelets in metastasis was obtained from a mouse
model in which experimental thrombocytopenia led to
attenuation of metastasis [19]. The significance of the
tumor cell microemboli formation was suggested when the
intravenous injection of tumor cells led to a rapid
association with platelets, whereas in the absence of this
interaction, tumor cells were cleared by natural killer (NK)
cells [20]. The intravenous tumor cell injection coincided
with a temporal reduction of peripheral platelet counts.
Interference with platelet–tumor cell interactions resulted in
the attenuation of metastasis, further supporting the
protective role of microemboli formation for tumor cell
survival [21, 22]. These “transit” metastatic emboli include
leucocytes and function as vehicles that shield the cancer
cell(s) from shear forces and immunosurveillance (NK
cells) [23], maintain viability of the cancer cell(s) through
signaling [24, 25], promote retention in capillaries, and
provide an in situ readily available repository of signaling
molecules that facilitate colonization of distant organs [26,
27] when the microembolic phase is initiated. Propagation–
prolongation of this process through maintenance of the
micro thrombosis-related microenvironment (activation of
cytokines and coagulation factors) promote establishment
of the “metastatic niche” (Fig. 1).
4.1 Coagulation factors and melanoma metastases
Coagulation factors, particularly thrombin and tissue factor
(TF), play an important role in melanoma metastasis [28–
31]. Thrombin stimulates platelets, induces tumor angio-
genesis, regulates tumor cell adhesion to platelets and
endothelial cells, and promotes tumor growth and metasta-
sis [28–30]. Thrombin responses in melanoma cell motility
and metastasis depend on proteinase-activated receptor-1
(PAR1) [32]; PAR1 is also required in the development of
TF-mediated metastasis [33]. The PAR1 expression is
significantly higher in metastatic melanoma cells, which
however have undetectable levels of endogenous activator
protein 2 (AP-2) [30, 32]. The loss of transcription factor
AP-2 is a crucial event in the development of malignant
melanoma [34] and results in overexpression of PAR1 that
regulates the metastatic phenotype of melanoma [35]b y
induction of cell adhesion molecules, matrix-degrading
proteases, stimulating the secretion of angiogenic and
invasive factors [30, 36–38]. PAR1 and thrombin could be
potential targets for antitumor and anti-metastasis therapy
for melanoma patients [30, 35, 37]. The data contribute to a
mechanistic explanation of the preclinical data that have
persistently pointed to potential anti-metastatic properties of
anticoagulants [30, 39] via effects on the coagulation
cascade.
5 Endothelial accesses and the metastatic process
The arrest of cancer cells in small vessels is an important step
in metastasis. Although simple mechanical entrapment has
been proposed [40, 41], more complex processes are
involved [26, 39, 42–44] including the alteration of cell
surface glycosylation, which is a common feature of
carcinoma progression and metastasis; in particular, high
expression of sialylated fucosylated glycans such as sialyl
Lewisx/a. A further significant role in these processes is
played by integrins [45] and although very recently, anti-
metastatic effects of heparins in melanoma have been
postulated to be mediated in certain cases though interaction
of heparin with integrins [46, 47], the complexity, diversity,
and the non-uniform impact of heparins [48] on this pathway
put a detailed discussion beyond the scope of this review.
5.1 Selectins and cell “docking”
Selectins are a family of mammalian vascular adhesion
molecules: P(latelet)-selectin, E(ndothelial)-selectin, and L
(eucocyte)-selectin [49]. Both E- and P-selectins are
inducible membrane proteins expressed on activated endo-
thelial cells or platelets following various proinflammatory
cytokine stimulations such as TNF and thrombin [50].
Selectins could interact with those sialyl Lewisx/a-contain-
ing cell surface glycoconjugates, normally found on mucin-
type glycoproteins of leukocytes and endothelium, and
mediate tethering, rolling, and adhesion of cells [49, 51,
52]. Thus, “deceleration” to achieve surface purchase is
achieved through cellular glycocalyx and selectin-mediated
interactions inducing “rolling”, in a manner that is similar
to that in the regulated recruitment of leukocytes to tissue
sites of damage and inflammation.
P-selectin has been demonstrated to mediate crucial
cancer cell interactions with platelets and endothelial cells
[39, 49, 51, 53]. The expression of E- and P-selectin on
endothelial cells initiates tethering and rolling of the cancer
cells and formation of weak adhesions to the endothelial
cells within the capillary bed [21]. Rolling is now thought
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melanoma cells prior to more definitive integrin-related
anchoring to the endothelium [54].
6 Heparins and melanoma metastases
6.1 The in vitro and preclinical evidence
The effect of the heparins on the melanoma metastatic
process has been repeatedly demonstrated since in both
experimental and spontaneous metastatic models (Table 1).
The emergence of the role of selectins regulating this
“docking” process of the cancer cell has pinpointed that at
least in the experimental tumor cell models the total effect
of heparin on the platelet–tumor cloak can be accounted for
by its interactions with P-selectin molecules [39, 55].
Moreover, these investigators and others [54, 56] have
demonstrated that the interactions of the cancer cell with P-
and E-selectins on endothelium are equally important for
adhesion and similarly a major therapeutic target of the
heparins [55, 57] (Fig. 1).
6.2 The proposed mechanism of the heparin–selectin
interaction
P-selectin binds a large range of heparin sulfate and heparin
fragments [57]. L-selectin may require a more specific
sequence for recognition. Although binding to Sialyl-Lewis
X motif on mucin-like molecules is thought to be a shared
ligand between the selectins, this interaction is weak [42,
58], and there is no clear superior single structural motif.
The suggested mechanism is that the recognition involves a
“clustered anionic patch”, rather than a linear-defined
oligosaccharide sequence. The most convincing high
affinity interaction discovered is that of P-selectin glyco-
Fig. 1 Potential role of hepa-
rin–selectin interaction in mela-
noma metastasis. a Platelet–
tumor cell microemboli forma-
tions are primarily mediated by
P-selectin and platelet aggrega-
tion. L-selectin mediates the
recruitment of leukocytes to
tumor cells. These “transit”
metastatic emboli include leu-
cocytes and function as vehicles
that shield the tumor cell from
shear force and immunosurveil-
lance (NK cells). The expression
of E- and P-selectin on endo-
thelial cells initiates tethering
and rolling of tumor cells. This
weak adhesion to the endotheli-
um promotes establishment of
the “metastatic niche” usually
associated with more “defini-
tive” binding to intercellular
cell adhesion molecules. b Hep-
arins bind to selectins and
inhibit their function
780 Cancer Metastasis Rev (2010) 29:777–784protein ligand-1 (PSGL-1) with P-selectin. This sialomucin
polypeptide is expressed on all leucocytes but becomes
specialized for selectin recognition on neutrophils and
monocytes. The most interesting biophysical aspect of
interaction of these molecules is that it involves novel “catch
bonds” which help to explain the rollin g behavior shown by
leucocytes coming into contact with endothelium [59, 60].
Unrelated glycans (e.g., the heparins) can also act as
ligands for L- and P-selectins and the clinically used
molecules (highly sulfated) are potent inhibitors, causing
complete inhibition of both L- and P-selectins in vitro assay
within recommended clinical anticoagulation target levels,
with unfractionated heparin being the most potent (Fig. 1).
Ludwig et al. [56, 61], employing the murine B16
melanoma lung metastasis model, revealed that heparin
treatment inhibited lung colonization (by >80%) if given
prior to, but not after intravenous inoculation of melanoma
cells. They showed that heparin inhibits melanoma rolling
in a P-selectin-dependent fashion. Whereas in P- selectin
−/−
mice rolling remained unaffected by heparin, in wild-type
mice heparin treatment reduced rolling of three different
melanoma cell lines (Mel1539, Mel624, and B16F10) in a
dose-dependent manner. Together, these data support the
assumption that both platelet and endothelial P-selectin are
potential targets of heparin action in melanoma metastasis
formation. These effects have been reproduced using an
orally administered heparin (a chemical conjugate of
LMWH and deoxycholic acid) in a murine melanoma lung
metastases model [54]. The LMWHs have similar effects but
IC50 values of these compounds against selectin–PSGL-1
Table 1 Preclinical and in vitro evidence of molecular targets of heparins in malignant melanoma
Molecular
target
Model Type of Heparin Mechanisms
Endothelial
P-selectin
B16F10 injected mice; murine B16F10,
human NW624 and NW1539 cells
UFH Heparin not only inhibits endothelial P-
selectin-mediated melanoma cell rolling
on microvasculature, but also attenuates
melanoma metastasis formation in vivo
[61].
P-selectin Human A375 cells Modified heparin Heparin can block P-selectin-mediated
A375 human melanoma cell adhesion
[67, 68].
P-selectin B16 injected mice; murine B16,
human NW624 and NW1539 cells
UFH; LMWHs (nadroparin, enoxaparin);
synthetic pentasaccharide fondaparinux
UFH and LMWHs inhibit P-selectin me-
diated rolling of melanoma cells in vitro
and in vivo [56].
P-selectin B16-BL6 injected mice;
murine B16-BL6 cell
Heparin derivatives Modified non-anticoagulant species of
heparin specifically inhibit selectin-
mediated cell–cell interactions, hepara-
nase enzymatic activity, or both [69].
Selectins B16F10 injected mice;
murine B16F10 cell
Orally absorbable heparin derivative
(LHD)
Orally active LHD could have anti-
metastatic effect via inhibition of cell–
cell interaction between melanoma cells
and platelets or HUVECs by interrupt-
ing selectin-mediated interactions [54].
Integrin
α4β1
(VLA-4)
Murine B16F10, human MV3 cells UFH; LMWH (tinzaparin),
a fraction of tinzaparin, fondaparinux.
Heparin is shown to interfere with the
VLA-4/VCAM-1 interaction and inhibit
integrin VLA-4-mediated interactions
[46, 70].
Integrin
αIIbβ3
B16F10 or A375 injected mice;
murine B16F10 and Human A375 cells
Modified heparins Modified heparins can inhibit melanoma
tumor cell–platelet interaction mediated
by platelet integrin αIIbβ3[ 47].
PAR1and
CD24
B16 and K1735 injected mice;
murine B16 and K1735 cells
LMWH (nadroparin) LMWH inhibits thrombin-dependent
PAR1 activation, thus, further inhibiting
the platelet or endothelial cell activation
and L- and P- selectin-mediated cell–cell
adhesion; cancer cell express CD24
takes part in metastasis as a ligand of P-
selectin. LMWH inhibits P-selectin/
CD24 interaction prevent binding of
platelets to cancer cells [71].
UFH unfractionated sodium heparin, LMWHs low molecular weight heparins
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therapeutic anticoagulation. This difference between unfrac-
tionated and LMW heparins is likely to be due to the
reduced efficacy of smaller-sized fragments interacting with
the “clustered anionic patch”. Nevertheless, even these
agents, dosed at therapeutic (rather than prophylactic) levels,
are highly effective selectin inhibitors [56, 61].
6.3 The clinical evidence
There has been a recent resurgence in the interest of the
potential effect of anticoagulants in cancer. Unfortunately,
the studies reported to date [62, 63], although hinting at
potential survival benefits from the use of LMWH, are
difficult to interpret as the populations studied are usually
mixed in terms of histology type and stage of cancer. It is
difficult to determine whether the effect is through
prevention of thrombosis (e.g., in mucin-producing adeno-
carcinomas) or through potential non-anticoagulant-
mediated anti-malignancy effects. Therefore, it is interest-
ing to consider the historical studies which, while smaller
and less robust, focused on specific cancers.
At least two studies in SCLC demonstrated a survival
benefit for those receiving unfractionated sodium heparin
(UFH) or LMWH [3, 64]. The thrombosis incidence in the
control groups was negligible but the benefit was signifi-
cant. This was difficult to explain and although it was
attributed to a better response rate at least in one study, we
suggest that other mechanisms relating to modification of
the natural history of this disease (such as reducing
incidence or delaying onset of brain metastases) may have
played a role. There are no data from these trials to support
or refute this hypothesis.
The data suggesting clinical role and effect of anti-
coagulants on melanoma have been previously summarized
[65, 66]. All the studies reviewed pointed to survival
benefit with anticoagulants although warfarin was the only
anticoagulant used in these early studies. Mechanisms
suggested were those of thrombin inhibition and possibly
beneficial effects on TF generation.
We therefore suggest that heparin or LMWH strategies
employed for their capacity to interfere with the metastatic
process have reasonable data in support and that the model
of prevention or delay of melanoma brain metastases could
be one that could elicit this benefit in a clinically
measurable sense (brain metastases-free interval) that could
also result in a patient relevant benefit in terms of survival.
7 Summary
The anti-metastatic mechanisms that may underpin the
effects of heparin–LMWH in in vitro and preclinical
melanoma models warrant testing in the clinical setting as
prevention or delay of brain metastases in melanoma
appears to be a clinically relevant and measurable target.
Studies to explore the effect of anticoagulants on cancer
survival are underway in other malignancies such as lung,
pancreas, ovary, breast, and stomach cancer. However, no
study to our knowledge has a methodology that could
produce clinical evidence in support of a mechanism for
whatever benefit may be seen. The “biological neuro-
protection” model we propose in metastatic melanoma
could provide this evidence, supporting the benefit of
LMWH in melanoma, but more significantly, opening the
door to a wider “anti-metastatic” approach that could have
much greater impact in patients with minimal disease being
treated in adjuvant settings for the more common malig-
nancies such as breast and colon cancer.
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